Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.010
Filtrar
1.
J Clin Rheumatol ; 27(6S): S308-S315, 2021 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-34525003

RESUMO

OBJECTIVE: To evaluate the reliability and validity of the Spanish version of the Medical Outcomes Study Pain Severity Scale (MOS-PSS) in patients with rheumatic diseases. METHODS: A cross-sectional study was carried out from January 2019 to March 2020 using a nonprobabilistic sampling of consecutive cases. The internal consistency of the scale was evaluated through the Cronbach α coefficient and by the item response theory reliability coefficient. Construct validity was evaluated by factor analysis; relationships between MOS-PSS and visual numeric scale for pain, numeric rating scale for pain, and verbal rating scale for pain; and differences between relevant groups. Item response theory-based methods were used to assess item performance. RESULTS: A clinical sample of 796 outpatients was recruited. Most patients presented moderate to severe pain. Two subscale solutions showed a good model fit in confirmatory factor analysis. The overall model fit of multidimensional generalized partial credit model showed to be adequate. The most discriminating item was "average pain intensity." Evidence revealed disordered thresholds in 2 items. Collapsing categories resulted in ordered thresholds for all items and significantly improving the overall model fit. The MOS-PSS and modified MOS-PSS yielded high reliability. Both scales were very strongly correlated with numeric rating scale for pain, visual numeric scale for pain, and verbal rating scale for pain (ρ ≥ 0.85). All hypotheses related to subgroups comparison were fulfilled. CONCLUSIONS: Overall, the Spanish version of the MOS-PSS showed good reliability and construct validity. Nevertheless, the statistical evidence from this study would suggest the modified MOS-PSS should be the version of choice for measuring pain in Mexican patients with rheumatic diseases.


Assuntos
Dor , Doenças Reumáticas , Estudos Transversais , Humanos , Dor/diagnóstico , Dor/epidemiologia , Dor/etiologia , Reprodutibilidade dos Testes , Doenças Reumáticas/diagnóstico , Inquéritos e Questionários
3.
Rev Med Inst Mex Seguro Soc ; 59(2): 127-132, 2021 Jun 14.
Artigo em Espanhol | MEDLINE | ID: mdl-34231984

RESUMO

Background: Infections increase morbidity and mortality in patients with autoimmune disorders; however, this association has not been established in rheumatic diseases and SARS-CoV-2 infection. Objective: To describe the clinical characteristics and mortality of patients with rheumatic diseases and severe COVID-19. Material and methods: Observational and descriptive case series in patients with rheumatic diseases and severe SARS-CoV-2 infection, confirmed by PCR or pulmonary tomography, hospitalized in Mexico City from March to August 2020. Results: 15 patients with a mean age of 57 years (SD ± 11) were included, 66.6% were women, and 80% had a positive PCR test. The time from onset of symptoms to hospitalization, on average, was 7.2 days (SD ± 2.1). 46.6% died. Patients who died had a lower mean platelet level compared to survivors. The inflammatory reactants were higher in the deceased. There were no statistically significant differences in mortality for the variables related to rheumatic disease. Conclusions: The differences in mortality of patients with severe COVID-19 in this series of cases seem to be related to the infection and not to the rheumatic disease.


Assuntos
COVID-19 , Doenças Reumáticas , Feminino , Hospitalização , Humanos , México/epidemiologia , Pessoa de Meia-Idade , Doenças Reumáticas/complicações , Doenças Reumáticas/diagnóstico , SARS-CoV-2
4.
Z Rheumatol ; 80(7): 641-646, 2021 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-34196793

RESUMO

The COVID-19 registry ( www.covid19-rheuma.de ) of the German Society of Rheumatology was the first registry for the acquisition and systemic evaluation of viral infections in patients with inflammatory rheumatic diseases (IRD). This has enabled rapid generation of scientific data that will help to improve the care of patients with IRD in the context of the pandemic. In addition to confirming general risk factors, such as patient age and comorbidities (e.g. cardiovascular, chronic lung and kidney diseases), the use of glucocorticoids and the disease activity of the rheumatic disease could be identified as disease-specific independent risk factors for the need of hospitalization due to COVID-19. Evaluations of the continuously growing cohort of patients with IRD and COVID-19 enable recommendations for patient care to be based on better evidence. Cooperation with international rheumatology registries (e.g. European COVID-19 registry for IRD) enables analyses of aggregated cohorts of patients with IRD and COVID-19 for international comparisons and statistically even more reliable statements.


Assuntos
COVID-19 , Doenças Reumáticas , Reumatologia , Humanos , Pandemias , Sistema de Registros , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/epidemiologia , SARS-CoV-2
5.
Rheumatol Int ; 41(8): 1441-1445, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-34142203

RESUMO

Patients with rheumatic and musculoskeletal (RMD) diseases may be at higher risks for COVID-19 infection. Data on the safety of the adenoviral vector-borne ChAdOx1 nCoV-19 and the heat-inactivated BBV152 Vaccines in this group are limited. 724 patients with RMD who had received at least one dose of either the ChAdOx1 or the BBV152 were audited to find out post-vaccination adverse effect (AE) or disease flares. The AE rates in patients with autoimmune rheumatic disease (AIRD) were compared with those with non-AIRD RMDs. The mean age of the cohort was 59.9 (± 10.43) years with a female (n = 581; 80.24%) majority. 523 (70.8%) had AIRD. The ChAdOx1 and the BBV152 vaccines were received by 624 (86.18%) and 77 (10.63%), respectively. 23 (3.17%) were unaware of which vaccine they had received. 238 (32.87%) of patients had at least one comorbidity. 436 (60.22%) participants [306 (59.64%) of those with AIRD and 130 (61.61%) with other RMDs] had at least one adverse effect (AE). Four patients reported flare of arthritis that resolved within 5 days. No patient had any severe AE or required hospitalization. All AEs were self-limiting. Both the ChAdOx1 and the BBV152 vaccines appear safe in RMDs. AEs do not differ between patients with AIRD or non-AIRD. This information can help negate vaccine hesitancy amongst all stakeholders.


Assuntos
Autoimunidade , Vacinas contra COVID-19/administração & dosagem , Doenças Reumáticas/imunologia , Idoso , Autoimunidade/efeitos dos fármacos , Vacinas contra COVID-19/efeitos adversos , Estudos Transversais , Feminino , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/tratamento farmacológico , Vacinação , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/efeitos adversos
7.
Harefuah ; 160(5): 276-278, 2021 May.
Artigo em Hebraico | MEDLINE | ID: mdl-34028217

RESUMO

INTRODUCTION: Following the appearance of the corona pandemic, international cooperation in pediatric rheumatology regarding registry of patients with rheumatic disease who have corona was launched within a few days. The parents' association initiated a similar patients' oriented registry. Following a large data collection showing that corona morbidity is low among children with rheumatic diseases, we could publish more evidence-based guidelines for physicians and patients. A similar registry for patients with hyper-inflammatory syndrome was also launched. The usage of telemedicine increased during that period.


Assuntos
COVID-19 , Doenças Reumáticas , Reumatologia , Criança , Humanos , Cooperação Internacional , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/epidemiologia , Doenças Reumáticas/terapia , SARS-CoV-2 , Síndrome de Resposta Inflamatória Sistêmica
8.
Arthritis Care Res (Hoboken) ; 73(8): 1146-1152, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-33973377

RESUMO

OBJECTIVE: The COVID-19 pandemic has had considerable economic repercussions for young workers. The current study was undertaken to examine the impact of the pandemic on the employment of young adults with rheumatic disease and on perceptions of work and health. METHODS: Surveys were administered to young adults with rheumatic disease prior to and following the onset of the COVID-19 pandemic. Surveys asked about employment status and collected information on sociodemographic, disease/health, and work-context factors. Items also asked about the perceived impact of the COVID-19 pandemic on work and health. A generalized estimating equation model was fitted to examine the effect of the pandemic on employment. RESULTS: In total, 133 young adults completed the pre-COVID-19 pandemic survey (mean age 28.9 years, 82% women). When compared to the pre-COVID-19 pandemic period, employment decreased from 86% to 71% following the pandemic, but no other changes were identified in sociodemographic, disease/health, or work-context factors. The time period following the COVID-19 pandemic was associated with a 72% lower odds of employment compared to the pre-pandemic period (odds ratio 0.28 [95% confidence interval 0.11-0.71]). Those with a postsecondary education or who reported more mental job demands were more likely to be employed following the onset of the pandemic. Also, a majority of participants reported that the pandemic affected health care (83%), treatment access (54%), working conditions (92%), and occupational health and safety (74%). CONCLUSION: The onset of the COVID-19 pandemic had socioeconomic implications for young people with rheumatic disease. To support economic recovery for individuals with rheumatic disease, strategies to promote employment should be designed that account for the young adult life phase and occupational characteristics.


Assuntos
COVID-19/epidemiologia , Emprego/tendências , Doenças Reumáticas/epidemiologia , Inquéritos e Questionários , Adulto , COVID-19/diagnóstico , Canadá/epidemiologia , Estudos de Coortes , Estudos Transversais , Feminino , Humanos , Estudos Longitudinais , Masculino , Pandemias , Doenças Reumáticas/diagnóstico
9.
Rheumatol Int ; 41(6): 1097-1103, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33856543

RESUMO

This study aimed to assess the baseline characteristics and clinical outcomes of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases and identify the risk factors associated with severe COVID-19 pneumonia. This was a retrospective study in a tertiary care center conducted through the period between March 2020 and November 2020 and included all adult patients with rheumatic diseases who tested positive on the COVID-19 polymerase chain reaction (PCR) test. We assessed the patients' demographic data, history of rheumatic disease, COVID-19 symptoms and experimental treatment, if any, their disease course, and outcome. In all, 47 patients were included, and most were females. The commonest rheumatic diseases were rheumatoid arthritis (53.2%), followed by systemic lupus erythematosus (21.3%), and psoriatic arthritis (10.6%). Methotrexate and hydroxychloroquine were the most commonly used disease-modifying anti-rheumatic drugs in 36.1% and 25.5%, respectively. Out of 47 patients, 48.9% required hospitalization with a median hospital stay of 7 days. Severe COVID-19 pneumonia, defined as clinical signs of pneumonia plus one of the following: respiratory rate > 30 bpm, severe respiratory distress, or oxygen saturation < 90% in room air was observed in 19.1% of the patients, and one patient died. We found that elderly patients with a mean age of 65.3 years were more likely to develop severe COVID-19 pneumonia and that was statistically significant. Our study showed that elderly patients with a mean age of 65 years and having rheumatic diseases had an increased risk of hospital admission and development of severe COVID-19 pneumonia.


Assuntos
COVID-19 , Doenças Reumáticas , Adulto , Idoso , Estudos de Coortes , Feminino , Humanos , Masculino , Estudos Retrospectivos , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/tratamento farmacológico , Doenças Reumáticas/epidemiologia , SARS-CoV-2
10.
RMD Open ; 7(1)2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33827969

RESUMO

AIM: To assess the impact of the COVID-19 pandemic on patients with rheumatic and musculoskeletal diseases (RMDs). METHODS: REUMAVID is a cross-sectional study using an online survey developed by an international multidisciplinary patient-led collaboration across seven European countries targeting unselected patients with RMDs. Healthcare access, daily activities, disease activity and function, well-being (WHO Five Well-Being Index (WHO-5)), health status, anxiety/depression (Hospital Anxiety and Depression Scale (HADS)) and access to information were evaluated. Data were collected in April-July 2020 (first phase). RESULTS: Data from the first phase included 1800 patients with 15 different RMDs (37.2% axial spondyloarthritis, 29.2% rheumatoid arthritis, 17.2% osteoarthritis and others). Mean age was 53, 80% female and 49% had undertaken university studies. During the beginning of the pandemic, 58.4% had their rheumatology appointment cancelled and 45.6% reported not having received any information relating to the possible impact of SARS-CoV-2 infection in their RMDs, with the main source being patient organisations (27.6%).Regarding habits, 24.6% increased smoking, 18.2% raised their alcohol consumption, and 45.6% were unable to continue exercising. Self-reported disease activity was high (5.3±2.7) and 75.6% reported elevated pain. Half the patients (49.0%) reported poor well-being (WHO-5) and 46.6% that their health had changed for the worse during lockdown. According to HADS, 57.3% were at risk of anxiety and 45.9% of depression. CONCLUSION: Throughout the first wave of the COVID-19 pandemic, patients with RMDs have experienced disruption in access to healthcare services, poor lifestyle habits and negative effects on their overall health, well-being and mental health. Furthermore, information on COVID-19 has not reached patients appropriately.


Assuntos
Ansiedade , COVID-19 , Depressão , Exercício Físico , Saúde Mental/estatística & dados numéricos , Doenças Musculoesqueléticas , Aceitação pelo Paciente de Cuidados de Saúde/estatística & dados numéricos , Doenças Reumáticas , Ansiedade/diagnóstico , Ansiedade/epidemiologia , COVID-19/epidemiologia , COVID-19/psicologia , Estudos Transversais , Depressão/diagnóstico , Depressão/epidemiologia , Europa (Continente)/epidemiologia , Feminino , Estado Funcional , Humanos , Estilo de Vida , Masculino , Pessoa de Meia-Idade , Doenças Musculoesqueléticas/diagnóstico , Doenças Musculoesqueléticas/epidemiologia , Doenças Musculoesqueléticas/psicologia , Gravidade do Paciente , Medidas de Resultados Relatados pelo Paciente , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/epidemiologia , Doenças Reumáticas/psicologia , SARS-CoV-2
11.
Nat Rev Rheumatol ; 17(6): 363-374, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33850309

RESUMO

Historically, rheumatic diseases have not received much attention in Africa, particularly in sub-Saharan Africa, possibly owing to a focus on the overwhelming incidence of infectious diseases and the decreased life span of the general population in this region. Global attention and support, together with better health policies and planning, have improved outcomes for many infectious diseases; thus, increasing attention is being turned to chronic non-communicable diseases. Rheumatic diseases were previously considered to be rare among Africans but there is now a growing interest in these conditions, particularly as the number of rheumatologists on the continent increases. This interest has resulted in a growing number of publications from Africa on the more commonly encountered rheumatic diseases, as well as case reports of rare diseases. Despite the limited amount of available data, some aspects of the epidemiology, genetics and clinical and laboratory features of rheumatic diseases in African populations are known, as is some detail on the use of therapeutics. Similarities and differences in these conditions can be seen across the multi-ethnic and genetically diverse African continent, and it is hoped that increased awareness of rheumatic diseases in Africa will lead to earlier diagnosis and better outcomes for patients.


Assuntos
Predisposição Genética para Doença/epidemiologia , Publicações/estatística & dados numéricos , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/epidemiologia , Reumatologistas/estatística & dados numéricos , Adulto , África ao Sul do Saara/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Antirreumáticos/uso terapêutico , Conscientização , Comorbidade , Gerenciamento Clínico , Meio Ambiente , Feminino , Predisposição Genética para Doença/etnologia , Política de Saúde , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Publicações/provisão & distribuição , Doenças Reumáticas/tratamento farmacológico , Doenças Reumáticas/genética , Fatores de Risco
12.
Medicine (Baltimore) ; 100(16): e25558, 2021 Apr 23.
Artigo em Inglês | MEDLINE | ID: mdl-33879708

RESUMO

ABSTRACT: Our aim was to investigate the newest generation anti-cyclic citrullinated peptide (CCP) antibody 3.1 assay in diagnosing rheumatoid arthritis (RA) compared with other autoimmune and non-autoimmune diseases. We performed a retrospective observational chart review of patients with a positive CCP level over a one-year period at a single academic institution and assessed the associated diagnoses after at least six-months of follow-up. Of the 281 CCP positive patients during that period, 48% had a diagnosis of RA. The positive predictive value of RA in patients with a high CCP 3.1 assay was 0.619 compared to 0.248 with a low positive CCP 3.1 assay (P < .0001). Overall, there was a lower than expected positive predictive value of CCP 3.1 level with an RA diagnosis, though the likelihood of having an RA diagnosis was higher with a higher CCP level.


Assuntos
Artrite Reumatoide/diagnóstico , Autoanticorpos/sangue , Doenças Autoimunes/diagnóstico , Peptídeos Cíclicos/imunologia , Doenças Reumáticas/diagnóstico , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Retrospectivos
13.
Z Rheumatol ; 80(4): 339-347, 2021 May.
Artigo em Alemão | MEDLINE | ID: mdl-33885947

RESUMO

Infections are a severe complication after an artificial joint replacement. The clinical symptoms are highly variable, particularly in patients with inflammatory rheumatic diseases, which often makes the diagnosis difficult. In addition to clinical and laboratory findings, joint puncture is an essential component of the diagnostics and enables the identification of pathogens. Treatment of periprosthetic infections in patients with rheumatism should be an interdisciplinary cooperation between surgeons, rheumatologists and specialists for infectious diseases. The two essential pillars of treatment are surgical intervention and antibiotics. For acute joint infections an attempt at preservation of the artificial joint can be carried out, whereas for chronic infection situations only replacement of the prosthesis is possible as a curative treatment. In order to reduce the probability of occurrence of a joint infection, modifiable risk factors should be preoperatively identified and specifically treated.


Assuntos
Artrite Infecciosa , Artroplastia de Quadril , Artroplastia de Substituição , Infecções Relacionadas à Prótese , Doenças Reumáticas , Humanos , Próteses e Implantes , Infecções Relacionadas à Prótese/diagnóstico , Infecções Relacionadas à Prótese/etiologia , Reoperação , Doenças Reumáticas/diagnóstico
15.
Z Rheumatol ; 80(5): 418-424, 2021 Jun.
Artigo em Alemão | MEDLINE | ID: mdl-33709166

RESUMO

BACKGROUND: Methotrexate (MTX) is the most commonly prescribed disease-modifying drug in the treatment of rheumatic diseases. Regular laboratory testing is recommended to recognize side effects, such as hepatotoxicity and myelotoxicity as well as decreases in renal function that may cause toxic MTX accumulation. Additionally, folic acid is recommended as prophylaxis against specific side effects. In this study we investigated whether laboratory monitoring and prescription of folic acid took place according to published recommendations. MATERIAL AND METHODS: Claims data from the statutory health insurance from 1 January 2009 to 31 December 2013 were retrospectively analyzed. A total of 40,087 adults with a rheumatic diagnosis (ICD10 codes M05-M18), no malignant disease and no previous MTX prescription within 12 months were extracted from the InGef (Institute for Applied Health Research in Berlin, formerly Health Risk Institute) research database. The frequency of recommended laboratory testing, appointments with rheumatologists and the prescription of folic acid prophylaxis were investigated. RESULTS: Of the patients 12,451 began treatment with MTX in the observation period. Between 42% and 46% of recommended blood counts, liver values and kidney function tests and 14% of urinalyses were performed according to recommendations. Of the patients 84% were seen regularly by a rheumatologist and 74% received a prescription for prophylactic folic acid. Serious conditions potentially resulting from MTX treatment were observed in 0.7-3.5 cases/1000 person years. DISCUSSION: Laboratory monitoring in the context of MTX treatment is carried out less frequently than recommended in the literature. Potential MTX-associated serious complications are rare from a practice perspective. On the one hand solutions are needed for a better coordination of laboratory monitoring. On the other hand more empirical evidence is needed regarding the benefits of laboratory monitoring and the appropriate intervals thereof.


Assuntos
Antirreumáticos , Artrite Reumatoide , Doenças Reumáticas , Adulto , Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Humanos , Laboratórios , Metotrexato/efeitos adversos , Segurança do Paciente , Estudos Retrospectivos , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/tratamento farmacológico
16.
Arthritis Res Ther ; 23(1): 89, 2021 03 19.
Artigo em Inglês | MEDLINE | ID: mdl-33741041

RESUMO

BACKGROUND: Several studies on community populations found that metabolic syndrome (MetS) is associated with higher risk for total incident cancer with a predisposition for specific types of cancer. These findings have never been analyzed in patients with chronic inflammatory rheumatic and musculoskeletal diseases (RMD). We assessed prevalence/incidence and factors related to the development of cancer in a large cohort of these patients and evaluate whether MetS and its components were associated with cancer independent of traditional markers of inflammation. METHODS: Between March 2014 and April 2016, 474 patients with RMD involved in a cardiovascular primary prevention program were consecutively recruited into this ambispective (combination of retrospective/prospective) study. They underwent clinical, laboratory, and echocardiographic evaluations. MetS was diagnosed according to the ATPIII criteria. RESULTS: Duration of follow-up was 42 [18-60] months. Patients with a diagnosis of cancer (made before recruitment or during follow-up) were 46 (9.7%). Cancer was diagnosed in 22/76 patients (29%) with MetS and in 24/398 patients (6%, p < 0.001) without MetS; nearly two thirds of malignancies belonged to those traditionally related to MetS. MetS was the strongest cancer risk factor. Cancer was positively associated with the number of MetS components identified in each patient. Beyond MetS, cancer was associated to older age and increased inflammatory disease activity; this information allowed to build a simple performance indicator highly sensitive for cancer development. CONCLUSION: In light of our results, an increasingly accurate assessment of MetS would be required in patients with RMD as potential measure of clinical outcomes including the risk of cancer.


Assuntos
Síndrome Metabólica , Neoplasias , Doenças Reumáticas , Idoso , Humanos , Síndrome Metabólica/diagnóstico , Síndrome Metabólica/epidemiologia , Neoplasias/epidemiologia , Prevalência , Estudos Prospectivos , Estudos Retrospectivos , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/epidemiologia , Fatores de Risco
18.
Eur J Med Genet ; 64(4): 104185, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33662637

RESUMO

Musculoskeletal symptoms may be due to noninflammatory causes, including genetic disorders. We aimed to examine the final genetic diagnosis in patients who presented with musculoskeletal complaints to the rheumatology department. Patients who presented to the Department of Pediatric Rheumatology and were referred to the pediatric genetic department between January 2015 and May 2019 were evaluated retrospectively. A total of 60 patients, 19 boys (31.66%), with a mean age of 12.46 ± 1.41 years were included in the study. The total consanguinity rate was 25%. The most common (29.5%) cause of referral to the pediatric genetic department was the presence of skeletal anomalies (such as camptodactyly, clinodactyly, and short stature) with accompanying joint findings. Approximately one-third of the patients (n: 19) were diagnosed and followed up by the pediatric genetics department. The diagnoses of patients were as follows: camptodactyly, arthropathy, coxa vara, and pericarditis (CACP) syndrome (n: 3); trichorhinophalangeal syndrome (n: 1); progressive pseudorheumatoid dysplasia (n: 2); LIG4 syndrome (n: 1); H syndrome (n: 1); spondyloenchondrodysplasia (SPENCD) (n: 3); and nonspecific connective tissue disorders (n: 8). In the differential diagnosis of patients who are referred to the Department of Pediatric Rheumatology with complaints of the musculoskeletal system, genetic disorders should also be considered.


Assuntos
Testes Genéticos/normas , Deformidades Congênitas dos Membros/genética , Doenças Reumáticas/genética , Adolescente , Criança , Diagnóstico Diferencial , Feminino , Testes Genéticos/métodos , Humanos , Deformidades Congênitas dos Membros/diagnóstico , Deformidades Congênitas dos Membros/diagnóstico por imagem , Masculino , Radiografia/normas , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/diagnóstico por imagem
20.
Front Immunol ; 12: 645013, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33777042

RESUMO

Background: Numerous cases of the coronavirus disease 2019 (COVID-19) with autoimmune and rheumatic manifestations have been reported. Despite the available reviews that summarized its autoimmune/rheumatic manifestations, a systematic approach is still lacking. Therefore, we conducted a comprehensive systematic review in order to give an overview upon these rare but clinically significant manifestations. Methods: We performed a literature search of PubMed and EMBASE as of October 9, 2020. All articles relevant to either systemic or organ-specific autoimmune and rheumatic manifestations potentially associated with COVID-19 were collected. The reviewed literature were limited to adults ≥18 years. Results: Although most of the existing evidence was based on case reports or case series without a long-term follow-up, a variety of autoimmune/rheumatic manifestations were associated with COVID-19. The manifestations that have a consistent association with COVID-19 include autoimmune cytopenia, cutaneous vasculitis, encephalitis, and Guillain-Barre syndrome. Such association is conflicting as regards to antiphospholipid syndrome, hemophagocytic lymphohistiocytosis, and myasthenia gravis. Conclusion: Our systematic review indicated the potential of the COVID-19 virus to trigger a myriad of autoimmune and rheumatic manifestations, which should be considered amid global efforts to combat COVID-19.


Assuntos
Doenças Autoimunes/imunologia , Autoimunidade , COVID-19/imunologia , Doenças Reumáticas/imunologia , SARS-CoV-2/imunologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças Autoimunes/diagnóstico , Doenças Autoimunes/epidemiologia , COVID-19/diagnóstico , COVID-19/epidemiologia , COVID-19/virologia , Criança , Pré-Escolar , Feminino , Interações Hospedeiro-Patógeno , Humanos , Masculino , Pessoa de Meia-Idade , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/epidemiologia , Doenças Reumáticas/virologia , SARS-CoV-2/patogenicidade , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...